咖啡摄入、咖啡因代谢基因型与主动监测下局限性前列腺癌的疾病进展
前瞻性主动监测队列纳入411例新诊断Gleason 6或7分前列腺癌患者,基线评估咖啡摄入并检测rs762551基因型。中位随访36个月,76例(18.5%)Gleason评分进展;各咖啡摄入量组与无进展生存均无显著关联,但低/中度摄入且AA快代谢基因型者进展风险低于不饮用者(HR 0.36,95%CI 0.15-0.88,P=0.03)。
要点
- 局限性前列腺癌主动监测中,低至中度咖啡摄入未显示与疾病进展显著相关。
- AA快代谢基因型且低/中度咖啡摄入者Gleason进展风险低于不饮用者。
- 高咖啡摄入(≥4杯/日)与无进展生存的关联不显著,需进一步研究。
核心结论
- 低至中度咖啡摄入在主动监测的局限性前列腺癌患者中似乎是安全的。
- 高摄入是否与敏感人群无进展生存缩短相关尚需进一步研究。
研究设计与样本
- 前瞻性主动监测方案纳入411例新诊断Gleason评分6或7分前列腺癌患者,监测至少6个月并完成基线饮食评估。
- 主动监测方案包括每两年一次监测,疾病进展定义为Gleason评分升高。
- 采用Cox比例风险模型评估咖啡摄入与无进展生存的关联,并检测咖啡因代谢相关单核苷酸多态性rs762551。
主要发现
- 中位随访36个月(范围6至126),411例中76例(18.5%)Gleason评分进展。
- 与每日0杯相比,多变量模型(校正前列腺特异性抗原、年龄和肿瘤长度)中<1杯(HR 0.85,95%CI 0.40-1.71)、1-1.9杯(HR 0.64,95%CI 0.29-1.43)、2-3.9杯(HR 0.71,95%CI 0.35-1.47)和≥4杯(HR 1.67,95%CI 0.81-3.45)与无进展生存均无显著关联(非线性P=0.01)。
- 低/中度咖啡摄入且AA快咖啡因代谢基因型患者较不饮用者更少发生分级进展(HR 0.36,95%CI 0.15-0.88,P=0.03)。
临床怎么用
- 对主动监测的局限性前列腺癌患者,可告知低至中度咖啡摄入未显示增加进展风险。
- 咖啡摄入与进展风险的关联可能受咖啡因代谢基因型影响,但暂不作为常规检测推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Active surveillance is increasingly used as a management strategy for localized prostate cancer. Coffee intake has been associated with a lower prostate cancer incidence. We assessed whether coffee was associated with disease progression in men on active surveillance. MATERIALS AND METHODS: A total of 411 patients with newly diagnosed Gleason score 6 or 7 prostate cancer were enrolled on a prospective active surveillance protocol for at least 6 months and completed a baseline dietary assessment. The active surveillance protocol included a biennial monitoring regimen with disease progression defined as an increase in the Gleason score. Cox proportional hazards models were used to evaluate associations of coffee intake with progression-free survival. We also evaluated patient genotype in the caffeine metabolism related single nucleotide polymorphism rs762551. RESULTS: Median followup was 36 months (range 6 to 126) and the Gleason score progressed in 76 of the 411 patients (18.5%). Compared to 0 cups per day, in the multivariable model adjusting for prostate specific antigen, patient age and tumor length, less than 1 cup (HR 0.85, 95% CI 0.40-1.71), 1 to 1.9 cups (HR 0.64, 95% CI 0.29-1.43), 2 to 3.9 cups (HR 0.71, 95% CI 0.35-1.47) and 4 cups or more (HR 1.67, 95% CI 0.81-3.45) were not significantly associated with progression-free survival (p for nonlinearity = 0.01). Patients with low/moderate coffee intake and the AA fast caffeine metabolizer genotype were less likely to experience grade progression than nonconsumers (HR 0.36, 95% CI 0.15-0.88, p = 0.03). CONCLUSIONS: Low to moderate coffee intake appears safe in men on active surveillance of localized prostate cancer. Further work is needed to determine whether high consumption is associated with shorter progression-free survival in sensitive groups.
引用
- Gregg JR, Lopez DS, Reichard C, et al. Coffee, Caffeine Metabolism Genotype and Disease Progression in Patients with Localized Prostate Cancer Managed with Active Surveillance. J Urol. 2019. PMID: 30179617. doi:10.1016/j.juro.2018.08.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。